Healthcare Services

Vancomycin Market Future Outlook Showing Expansion Toward $1.46 Billion by 2030

April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Vancomycin Market In 2026 And What Value Is Projected For 2030?

The vancomycin market size has shown swift expansion recently. It is projected to increase from $0.91 billion in 2025 to $1.01 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.8%. This historical growth can be linked to the increasing prevalence of gram-positive bacterial infections, elevated hospital admission rates, the initial embrace of vancomycin as a last-resort treatment, the development of intensive care infrastructure, and the rising occurrence of antibiotic resistance.

The vancomycin market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach $1.46 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.8%. Factors contributing to this growth during the forecast period include a growing need for sophisticated injectable antibiotics, heightened emphasis on infection prevention measures, the proliferation of hospital pharmacy automation, increased funding for antimicrobial research, and more stringent regulatory control over antibiotic administration. Key trends anticipated during the forecast period involve a heightened demand for glycopeptide antibiotics, an intensified focus on managing hospital-acquired infections, the wider availability of ready-to-use injectable formulations, a greater commitment to antimicrobial stewardship initiatives, and improved surveillance of drug resistance profiles.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16563&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Vancomycin Market?

The expanding occurrence of infectious diseases is anticipated to fuel the expansion of the vancomycin market in the future. These diseases are health conditions stemming from pathogenic microorganisms like bacteria, viruses, fungi, or parasites, including ailments such as influenza, tuberculosis, malaria, HIV/AIDS, and COVID-19. The escalating incidence of infectious diseases can be linked to elements such as antimicrobial resistance, climate change, and population growth. Vancomycin plays a crucial role in addressing serious gram-positive bacterial infections, particularly those involving resistant strains, with its use informed by clinical guidelines and antimicrobial stewardship to ensure the best patient outcomes. As an illustration, in October 2024, data from the World Health Organization, an international public health body based in Switzerland, showed that around 8.2 million individuals received a new diagnosis of tuberculosis in 2023, an increase from approximately 7.5 million in 2022, thereby identifying tuberculosis as the foremost infectious disease fatality cause. Consequently, the heightened prevalence of infectious diseases is propelling the expansion of the vancomycin market.

What Are The Key Segments Of The Vancomycin Market?

The vancomycin market covered in this report is segmented –

1) By Type: Injectable Solution, Powder For Injection

2) By Route Of Administration: Intravenous, Oral

3) By Application: Sepsis, Lung Infection, Skin Soft Tissue Infection, Colitis And Intestinal Inflammation, To Prevent Infection

Subsegments:

1) By Injectable Solution: Pre-Mixed Injectable Solution, Ready-To-Use Injectable Solution, Concentrated Injectable Solution

2) By Powder For Injection: Vancomycin Powder For Intravenous Use, Vancomycin Powder For Reconstitution

Which Trends Are Shaping The Future Of The Vancomycin Market?

Major entities operating within the vancomycin market are prioritizing the creation of advanced products, such as anti-infective and anti-hypotensive medications, to uphold their market standing. Anti-infective medications are medicines utilized to combat infections caused by bacteria, viruses, fungi, parasites, or other microorganisms. Anti-hypotensive medications are pharmaceutical agents employed to elevate blood pressure in individuals experiencing low blood pressure, or hypotension. For instance, in April 2024, Baxter International Inc., a US-based healthcare company, unveiled the introduction of five injectable products in the US, as a component of its continuous expansion in its pharmaceutical portfolio. These new injectable products are formulated to target particular medical demands, including progress in anesthesia, pain management, and specialized therapies, demonstrating the firm’s dedication to supplying healthcare practitioners with effective resources to enhance patient results.

Who Are The Leading Companies Operating In The Vancomycin Market?

Major companies operating in the vancomycin market are ANI Pharmaceuticals Inc., Alvogen Inc., Xellia Pharmaceuticals ApS, Sagent Pharmaceuticals, Fresenius Kabi AG, Lupin Limited, Eugia Pharma Specialities, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals, Slate Run Pharmaceuticals, Alkem Laboratories Ltd., Azurity Pharmaceuticals, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi SA, Bayer AG, GlaxoSmithKline plc, Merck & Co Inc., Aurobindo Pharma Limited, Cipla Inc., Johnson & Johnson, Bristol-Myers Squibb Company, AbbVie Inc., Janssen Global, Shenwei Pharmaceutical Hainan Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Sun Pharmaceutical Industries Ltd., Viatris Inc., North China Pharmaceutical Group, Taiwan Zhengde Pharmaceutical, LegoChem Biosciences, Nabriva Therapeutics, MicuRx Pharmaceuticals, MGB Biopharma Limited, VIANEX

Read the full vancomycin market report here:

https://www.thebusinessresearchcompany.com/report/vancomycin-global-market-report

What Are The Leading Geographic Regions In The Vancomycin Market?

North America was the largest region in the vancomycin market in 2025. The regions covered in the vancomycin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Vancomycin Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16563&type=smp

Browse Through More Reports Similar to the Global Vancomycin Market 2026, By The Business Research Company

Levofloxacin Global Market Report

https://www.thebusinessresearchcompany.com/report/levofloxacin-global-market-report

Antibiotics Global Market Report

https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report

Macrolide Antibiotics Global Market Report

https://www.thebusinessresearchcompany.com/report/macrolide-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795